May 24, 2016 | By DEEPTI RAMESH
Fermion expands API manufacturing facility in Finland Fermion (Espoo, Finland), a manufacturer of active pharmaceutical ingredients (APIs), says that it is expanding its API production capacity at Hanko, Finland. Fermion is investing €30 million ($33.6 million) in the expansion, which is the largest in the history of the company since it was formed in 1970. The expansion project has the necessary...
May 17, 2016 | By DEEPTI RAMESH
Strides Shasun to sell API facility in UK for £25 million Pharmaceutical company Strides Shasun (Bangalore, India), which was formed through the merger of Strides Arcolab and Shasun Pharmaceuticals last year, informed the Bombay Stock Exchange (Mumbai) on 16 May that its board of directors has approved the divestment of Shasun Pharma Solutions Ltd. (Dudley, UK), which is involved in the business of...
May 10, 2016 | By DEEPTI RAMESH
AMRI to acquire Italy-based API manufacturer for $358 million Albany Molecular Research Inc. (AMRI; Albany, NY) says that it has signed a definitive agreement to acquire Prime European Therapeuticals (Lodi, Italy), also known as Euticals, in a transaction valued at approximately $358 million, consisting of shares of AMRI common stock, cash, and a seller note. Euticals, which was established in 1984, is a...
May 9, 2016 | By ROB WESTERVELT
Our cover story this week looks at the transformation and impact of chemical industry R&D (p. 19). Investment is increasingly shorter term, and it is moving closer to customers and growth regions. Chemical makers are collaborating more and with a variety of partners to share cost and risk and quicken development...
May 3, 2016 | By DEEPTI RAMESH
Cambrex reports rise in profits, sales increase on higher volumes Cambrex (East Rutherford, NJ) reports an 82.4% rise in net profits for the first quarter of 2016 compared with the first quarter of 2015, to $14.58 million. First-quarter sales increased 20.1%, to $93.9 million. Foreign exchange unfavorably impacted reported sales growth by 1%, Cambrex says. The sales increase primarily reflects higher...
April 26, 2016 | By DEEPTI RAMESH
PCI forms cGMP advanced polymer development and manufacturing unit PCI Synthesis (Newburyport, MA), a manufacturer of new chemical entities, generic active pharmaceutical ingredients (APIs), and other specialty chemical products, has formed a cGMP advanced polymer development and manufacturing group. The group is currently developing and manufacturing more than a dozen advanced polymer-based projects...
April 19, 2016 | By DEEPTI RAMESH
Dottikon reports higher sales as demand rises Fine chemicals company Dottikon Exclusive Synthesis (Dottikon ES; Dottikon, Switzerland) reports sales of 121.4 million Swiss francs ($125 million) for the full fiscal year ended 31 March 2016, an increase of 26% over the previous fiscal year. The sales growth was purely organic, the company says. Dottikon ES says it will report its net profits for the fiscal...
April 12, 2016 | By DEEPTI RAMESH
Dr. Reddy’s and CutisPharma enter into API supply and joint development agreements CutisPharma (Wilmington, MA), a specialty pharmaceutical company, says that it has entered into active pharmaceutical ingredient (API) supply and joint development agreements with Dr. Reddy’s Laboratories (Hyderabad, India) to advance several programs in CutisPharma’s R&D portfolio toward FDA approval...
April 5, 2016 | By DEEPTI RAMESH
API business of Grindeks reports fall in sales Pharmaceutical company Grindeks' (Riga, Latvia) active pharmaceutical ingredients (API) business reports a 20.3% fall in sales in 2015 compared with 2014, to €7.2 million ($8.2 million). The company’s main API export markets are Canada, Japan, countries in the European Union, and the United States. In the company’s API business, demand was...
March 29, 2016 | By DEEPTI RAMESH
Siegfried reports rise in profits, sales following acquisition of BASF pharma ingredients businesses Siegfried (Zofingen, Switzerland) reports a 1.4% rise in net profits for 2015, compared with 2014, to 39.1 million Swiss francs ($40.2 million). Full-year sales in 2015 increased 52.4%, to SF480.6 million. Ebitda increased by 31.3% in 2015, to SF77.1 million. Fourth-quarter figures have not been disclosed...
ABOUT CHEM IDEAS
Welcome to Chem Ideas, the place for opinions and perspective on the key issues affecting the global chemicals industry. This zone features articles by Chemweek’s regular editors as well as a team of established experts with insights across the chemicals industry. If you would like to contribute a blog or opinion piece contact firstname.lastname@example.org.
Not an IHS Chemical Week member yet?
Here's why you should be:
- 31 issues of Chemical Week magazine in print or digital format
- Critical daily news and analysis from the entire global chemical enterprise on chemweek.com
- Free mobile edition of Chemical Week
- 20+ years of online archives
- Topical e-newsletters that capture the most impactful events
- Special issues with a regional focus
- Global outlook issue
100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.